Inducible dominant negative ErbB2 rat spermatogonial line for generation of transgenic rat model and dissecting ERBB2 tyrosine kinase mediated pathways
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13026Keywords:
cancer, clonal analyses, ERBB2, Her2/neu, spermatogonial stem cell, transgene expression, transgenic ratAbstract
Summary. Aim: The ERBB2 receptors tyrosine kinase, also known as HER2/Neu, play an essential role in early organism development and modulation of cell behavior in varieties of tissue in an adult organism. Our aim was the generation of transgenic rat spermatogonial line capable of inducible expression of a dominant negative form of the ERBB2 protein in vitro and the transgenic rat as an animal model for dissection of the ERBB2 mediated signaling in vitro and in vivo. Materials and Methods: Donor derived rat spermatogonial stem cells that express green fluorescence protein and inducible ERT2CreERT2 recombinase were modified with Sleeping Beauty transposon-based vector that express truncated kinase deficient form of the ERBB2 receptor upon Cre mediated recombination. Clonally selected spermatogonial cell lines were extensively tested in vitro. Animals were generated via spermatogonia mediated transgenesis by transplantation of clonal cell line into testes of chemically sterilized recipients. Obtained progeny were tested for inducibility in vivo and served as donors of spermatogonia for downstream analysis. Results: We obtained animals and clonally derived spermatogonial stem cell lines that express an inducible dominant negative form of the ERBB2 protein. Isogenic nature of induced and uninduced cells allows most accurate morphological and molecular comparison of cells affected by the interruption of normal function of the ERBB2 receptor and cellular dynamics in vitro and in vivo. Conclusions: Clonally derived spermatogonial stem cell lines that express an inducible dominant negative form of ErbB2 demonstrated an obvious difference in morphological appearance and growth kinetics of induced cells comparing to uninduced ones. Western blot analysis of induced and uninduced cells revealed significant differences in presence and phosphorylation state of several tested important proteins involved in the ERBB2 mediated signal transduction, such as S6 ribosomal protein; AKT (the serine/threonine kinase also known as protein kinase B); and three protein kinases that participate in the RAS-RAF-MEK-ERK signal transduction cascade PRAS40, MEK, ERK1/2.
References
Robinson DR, Yi-Mi W, Su-Fang L. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548–57.
Brea MS, Díaz RG, Escudero DS, et al. Epidermal growth factor receptor silencing blunts the slow force response to myocardial stretch. J Am Heart Assoc 2016; 15: e004017.
Donnenberg AD, Meyer EM, Rubin JP, Donnenberg VS. The cell-surface proteome of cultured adipose stromal cells. Cytometry A 2015; 87: 665–74.
Hoffmann I, Eugène E, Nassif X, et al. Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis. J Cell Biol 2001; 155: 133–44.
Oda Y, Wehrmann B, Radig K, et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 1995; 141: 97–103.
Scheving LA, Zhang X, Stevenson MC, et al. Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol 2015; 309: 942–54.
Tao R-H, Maruyama IN. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 2008; 121: 3207–17.
Torp SH, Helseth E, Dalen A, Unsgaard G. Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother 1991; 33: 61–4.
Roskoski RJ. The ErbB/HER family of protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1–11.
Thompson DM, Gill GN. The EGF receptor: structure, regulation, and potential role in malignancy. Cancer Surv 1985; 4: 767–88.
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367–80.
Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18: 4910–8.
Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3: 224–37.
Ueda S, Ogata S, Tsuda H, et al. Thecorrelation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancre-atic ductal adenocarcinoma. Pancreas 2004; 29: 1–8.
Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor inglioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010; 12: 675–84.
Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276–87.
Adrienne G, Waks MD, Eric P, Winer MD. Breast cancer treatment: a review. JAMA 2019; 321: 288–300.
Elizalde PV, Cordo Russo RI, Chervo MF, Schillaci R. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer 2016; 23: 243–57.
Keisuke Abé, Ko Eto, Shin-ichi Abé. Epidermal growth factor mediates spermatogonial proliferation in newt testis. Reprod Biol Endocrinol 2008; 6: 7.
Chan R, Hardy WR, Laing MA, et al. The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development. Mol Cell Biol 2002; 22: 1073–8.
Erickson SL, O’Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124: 4999–5011.
Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor ErbB2 in neural and cardiac development. Nature 1995; 378: 394–8.
Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386–90.
Guy CT, Webster MA, Schaller M, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578–82.
Qian X, Dougall WC, Hellman ME, Greene MI. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene 1994; 9: 1507–14.
Qian X, O’Rourke DM, Zhao H, Greene MI. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 1996; 13: 2149–57.
Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998; 188: 589–96.
Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 1999; 18: 3481–90.
Andrechek ER, Hardy WR, Siegel PM, et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 2000; 97: 3444–9.
Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16: 143–50.
Andrechek ER, Hardy WR, Laing MA, Muller WJ. Germ-line expression of an oncogenic ErbB2 allele confers resistance to ErbB2-induced mammary tumorigenesis. Proc Natl Acad Sci USA 2004; 101: 4984–9.
Syvyk T, Syvyk A. Customized transgenesis via modification of spermatogonial stem cells. J Microbiol Biotechnol Food Sci 2018; 7: 475–9.
Morris JK, Lin W, Hauser C, et al. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 1999; 23: 273–83.
Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459–65.
Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Nat Acad Sci 2002; 99: 8880–5.
Crone SA, Negro A, Trumpp A, et al. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 2003; 37: 29–40.
Iannaccone PM, Jacob HJ. Rats! Dis Model Mech 2009; 2: 206–10.
Cronkhite JT, Norlander C, Furth JK, et al. Male and female germline specific expression of an EGFP reporter gene in a unique strain of transgenic rats. Devel Biol 2005; 284: 171–83.
Wu Z, Falciatori I, Molyneux LA, et al. Spermatogonial culture medium: an effective and efficient nutrient mixture for culturing rat spermatogonial stem cells. Biol Reprod 2009; 81: 77–86.
Chapman KM, Saidley-Alsaadi D, Syvyk AE, et al. Rat spermatogonial stem cell-mediated gene transfer. In: Pease S, Saunders T, eds. Advanced Protocols for Animal Transgenesis: An ISTT Manual. Springer Protocols Handbooks. Springer, Berlin, Heidelberg, 2011: 237–66.
Syvyk TL, Dyachenko LS, Syvyk AE. Advancing recovery and cryopreservation of rat spermatogonia for germ stem cell banking. Biopol Cell 2018; 34: 196–206.
Syvyk TL, Djachenko LS, Syvyk AE. Optimization of freezing conditions for cryopreservation of rat spermatogonia stem cell. J Microbiol Biotechnol Food Sci 2018; 8: 947–50.
Ivics Z, Izsvák Z, Chapman KM, Hamra FK. Sleeping Beauty transposon mutagenesis of the rat genome in spermatogonial stem cells. Methods 2011; 53: 356–65.
Colombo M, Corsi F, Foschi D, et al. HER2 targeting as a two-sided strategy for breast cancer diagnosisand treatment: outlook and recent implications in nanomedical approaches. Pharmacol Res 2010; 62: 150–65.
Flaherty KT, Infante JR, Daud A, et al. Com-bined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med 2012; 367: 1694–703.
Gomez GG, Wykosky J, Zanca C, et al. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med 2013; 10: 192–205.
Sahin Ö, Fröhlich H, Löbke C, et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 2009; 3: 1.
Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018; 19: 17.
Li C, Li X, Gao S, et al. MicroRNA-133a inhibits proliferation of gastric cancer cells by downregulating ERBB2 expression. Oncol Res 2017; 25: 1169–76.
Wang S, Liu X, Wang W, et al. The effects of silencing the Her2 gene on proliferation and angiogenesis of meningioma cells in vivo and in vitro. Ann Clin Lab Sci 2018; 48: 580–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
